Lexicon Pharmaceuticals Announces It Will Present New Preclinical Data At The 9th International Congress On Neuropathic Pain 2025 ShowingThat Pilavapadin Reduces Neuropathic Pain In Models Of Chemotherapy-induced Peripheral Neuropathy And Multiple Sclerosis

Author: Benzinga Newsdesk | September 04, 2025 08:36am

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin's novel target, AAK1, for the modulation of pain signaling. The conference is being held September 4 – 6, 2025 in Berlin, Germany.

Presentation details:

• Poster: LX9211, a Novel AAK1 Inhibitor, Alleviates Pain in Preclinical Models of Chemotherapy-induced Neuropathic Pain and Multiple Sclerosis
• Date: Saturday, September 6, 2025
• Time: 8:30 a.m. – 6:00 p.m. CEST
• Location: Exhibition Poster Area
• Presenter: Suma Gopinathan, Senior Vice President, Discovery, Lexicon Pharmaceuticals
  
   

"We are encouraged by the promising results with pilavapadin in preclinical models of CIPN and MS, which highlight the potential of pilavapadin in additional neuropathic pain indications beyond diabetic peripheral neuropathic pain (DPNP)," said Suma Gopinathan, Senior Vice President of Discovery for Lexicon. "These data build upon the robust body of evidence supporting AAK1 inhibition as a powerful target for diverse neuropathic pain conditions."

Separately, Lexicon will also present a poster entitled "Study Design and Rationale of PROGRESS: Pilavapadin in a Phase 2b, Dose-ranging, Double-blind, Placebo-controlled Study in Diabetic Peripheral Neuropathic Pain."

Posted In: LXRX